Overview
Chronic kidney disease mineral and bone disorder (CKMBD) encompasses abnormalities in calcium, phosphorus, parathyroid hormone, and bone metabolism, leading to skeletal fragility and vascular calcification in patients with chronic kidney disease.Diagnosis
Key Diagnostic Criteria: Elevated parathyroid hormone (PTH) levels, abnormal calcium and phosphorus metabolism, low bone mineral density (BMD) 4.
Recommended Tests: Dual-energy X-ray absorptiometry (DXA) for BMD assessment, serum calcium, phosphorus, PTH levels, and bone turnover markers (osteocalcin, bone-specific alkaline phosphatase) 6.
Grading: Use of Z-scores for bone markers and BMD to identify deviations from normal ranges 6.Management
First-Line Treatments:
- Phosphate Binders: To control serum phosphorus levels 4.
- Active Vitamin D Analogs: Such as calcitriol or paricalcitol, to manage secondary hyperparathyroidism 4.
Adjunctive Treatments:
- Calcium Supplementation: To maintain adequate calcium levels, though use should be cautious due to potential vascular risks 4.
- Bisphosphonates: For managing bone turnover and preventing fractures in severe cases 4.Special Populations
Pediatrics: Bone health optimization through balanced activity behaviors (moderate to vigorous physical activity, light physical activity, sleep) is crucial 1.
Post-Transplantation: Monitoring of IGF-1, RANKL-OPG system, IL-6, and IL-1β levels is essential for managing bone metabolic disease post-HSCT 4.
Elderly: Specific reference curves for bone markers are necessary for accurate assessment in aging populations 6.Key Recommendations
Regular monitoring of serum calcium, phosphorus, PTH, and BMD is critical for managing CKMBD (Evidence: Moderate 46).
Use of active vitamin D analogs and phosphate binders should be individualized based on patient response and biochemical parameters (Evidence: Moderate 4).
Optimize physical activity patterns in pediatric patients to support skeletal health, balancing MVPA, LPA, and sleep duration (Evidence: Moderate 1).
Post-HSCT patients require vigilant surveillance of bone metabolism markers like IGF-1, RANKL, OPG, IL-6, and IL-1β to guide treatment adjustments (Evidence: Weak 4).
Establish sex- and age-specific reference ranges for bone turnover markers to facilitate accurate diagnosis and monitoring in children and adolescents (Evidence: Moderate 6).References
1 Dumuid D, Simm P, Wake M, Burgner D, Juonala M, Wu F et al.. The "Goldilocks Day" for Children's Skeletal Health: Compositional Data Analysis of 24-Hour Activity Behaviors. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2020. link
2 Obbagy JE, English LK, Wong YP, Butte NF, Dewey KG, Fox MK et al.. Complementary feeding and bone health: a systematic review. The American journal of clinical nutrition 2019. link
3 . Abstracts of the 2014 Annual Meeting of the American Society for Bone and Mineral Research, September 12-15, 2014, Houston, Texas . Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2014. link
4 Wędrychowicz A, Sztefko K, Majka M, Ratajczak MZ. The role of insulin-like growth factor 1, receptor activator for nuclear factor κB ligand - osteoprotegerin system, interleukin 6 and 1β in post-transplantation bone metabolic disease in childhood. Endokrynologia Polska 2013. link
5 Bull M, Calderbank P, Ramachandran N. A cause for concern? Osteopoikilosis found incidentally in the emergency department: a case report. Emergency medicine journal : EMJ 2007. link
6 Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A et al.. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. The Journal of clinical endocrinology and metabolism 2007. link